Alembic Pharmaceuticals’ arm gets final nod for Clobetasol Propionate Foam

25 Apr 2022 Evaluate

Alembic Pharmaceuticals’ wholly owned subsidiary -- Aleor Dermaceuticals has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Clobetasol Propionate Foam, 0.05%. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD) Olux Foam, 0.05%, of Mylan Pharmaceuticals Inc.

Clobetasol Propionate Foam is a corticosteroid indicated for treatment of moderate to severe plaque psoriasis of the scalp and mild to moderate plaque psoriasis of non-scalp regions of the body excluding the face and intertriginous areas in patients 12 years and Older. Clobetasol Propionate Foam, 0.05% has an estimated market size of $10 million for twelve months ending December 2021.

The company has received a cumulative total of 165 ANDA approvals (141 final approvals and 24 tentative approvals) from USFDA.

Alembic Pharmaceuticals, a vertically integrated research and development pharmaceutical company, has been at the forefront of Healthcare since 1907.

Alembic Pharma Share Price

839.50 -12.80 (-1.50%)
29-Dec-2025 15:00 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1717.05
Dr. Reddys Lab 1269.60
Cipla 1495.35
Zydus Lifesciences 904.70
Lupin 2083.25
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×